Iterum Therapeutics has commenced the first Sulopenem for Resistant Enterobacteriaceae (SURE) trial, a Phase lll study of oral sulopenem against oral ciprofloxacin for the treatment of adult women with uncomplicated urinary tract infections (uUTI).

The randomised, multi-centre, double-blind trial is designed to measure efficacy, tolerability, and safety of the trial drug combination among around 1,364 patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

To be performed under a Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA), the SURE 1 trial will randomise the enrolled patients to receive either oral sulopenem twice daily for five days or oral ciprofloxacin twice daily for three days.

The trial’s primary endpoint is overall success, including combined clinical and microbiological success.

Secondary endpoints of the trial are microbiologic success in each study arm in the microbiologically evaluable population.

“Multi-drug resistance in UTIs is alarmingly high and growing globally, and current treatment options are failing.”

Top-line results from the trial are expected in the second half of next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Iterum Therapeutics chief scientific officer Michael Dunne said: “Multi-drug resistance in UTIs is alarmingly high and growing globally, and current treatment options are failing.

“In particular, resistance to fluoroquinolones continues to rise. Healthcare providers and their patients urgently need new oral options to effectively treat infections in the community such as UTIs.

“The US Food and Drug Administration (FDA) has recently strengthened existing warnings for the fluoroquinolone class and maintains that healthcare professionals should not prescribe fluoroquinolones to patients who have other treatment options for uUTI as the risks outweigh the benefits.”

UTI is one of the most common bacterial infections of bladder that primarily attacks women.

Up to 10% of women are estimated to have a urinary tract infection in a given year, while 50% of all women experience at least one UTI at some point in their lives.